Atlas Venture Life Science Advisors, LLC holds a concentrated book of 7 stocks worth $881.3M as of Q3 2026 (disclosed Aug 13, 2026, a ~0-day 13F lag). This quarter they opened Kailera Therapeutics, Inc. and trimmed Kymera Therapeutics Inc. Their largest long position is Kymera Therapeutics Inc at 37% of the equity book. Cloning the disclosed picks since 2025 would be +46% (+61.2%/yr). That is a simulation of the disclosed long book, not audited returns.
Growth of $10,000 cloning Atlas Venture Life Science Advisors, LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~0 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
87% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Atlas Venture Life Science Advisors, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 7 / 7 | $399.8M |
| NISA INVESTMENT ADVISORS, LLC | 7 / 7 | $318K |
| FMR LLC | 6 / 7 | $1.5B |
| BlackRock, Inc. | 6 / 7 | $836.7M |
| STATE STREET CORP | 6 / 7 | $648.8M |
| Siren, L.L.C. | 6 / 7 | $529.1M |
| VANGUARD CAPITAL MANAGEMENT LLC | 6 / 7 | $490.7M |
| UBS Group AG | 6 / 7 | $104.6M |
Ranked by how many of Atlas Venture Life Science Advisors, LLC's top 7 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Kymera Therapeutics, Inc. Common Stock | $326.5M | 2.85M | 37.1% | ▼−38% Reduced · −1.7M sh | |
| 2 | Dyne Therapeutics, Inc. Common Stock | $151.0M | 6.80M | 17.1% | ▼−26% Reduced · −2.3M sh | |
| 3 | Sionna Therapeutics, Inc. Common Stock | $131.8M | 3.00M | 15.0% | —Held | |
| 4 | Kailera Therapeutics, Inc. Common Stock | $113.9M | 5.17M | 12.9% | ▲New New position | |
| 5 | Disc Medicine, Inc. Common Stock | $110.7M | 1.51M | 12.6% | —Held | |
| 6 | Q32 Bio, Inc. Common Stock | $34.6M | 2.72M | 3.9% | ▲+30% Added · +625K sh | |
| 7 | Korro Bio, Inc. Common Stock | $12.7M | 962.9K | 1.4% | ▼−15% Reduced · −174K sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1917529/holdings"
Use Arkolith to show Atlas Venture Life Science Advisors, LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.